Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kalvista Pharmaceuticals Inc 55 Cambridge Parkway Suite 901E CAMBRIDGE MA 02142 USA

www.kalvista.com P: 857-999-0075 F: 866-553-3269

Description:

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 631,132
Enterprise Value, $K 599,342
Shares Outstanding, K 42,188
Annual Sales, $ 0 K
Annual Net Income, $ -92,910 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -44,650 K
EBIT, $ -140,450 K
EBITDA, $ -139,540 K
60-Month Beta 0.91
% of Insider Shareholders 12.30%
% of Institutional Shareholders 0.00%
Float, K 36,999
% Float 87.70%
Short Volume Ratio 0.35

Growth:

1-Year Return 58.09%
3-Year Return -29.67%
5-Year Return -11.58%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -149.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.02 on 07/11/24
Next Earnings Date 09/05/24
Earnings Per Share ttm -3.40
EPS Growth vs. Prev Qtr -21.43%
EPS Growth vs. Prev Year -32.47%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 11/22/16

KALV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -110.97%
Return-on-Assets % -91.98%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.88
Book Value/Share 4.86
Interest Coverage -1.33
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar